Our Blog

12 Oct

Mesoblast join with Tasly for China deal

By Finance News

12 Oct 2018 – Regenerative medicine comapny Mesoblast (ASX:MSB) today announced completion of the transaction with Tasly Pharmaceutical Group to establish a strategic partnership in China for Mesoblast’s product candidates for heart failure.


Source: Finance News Network

Share this post

Related Posts

21 Nov

Stockland divests $113m for retail assets

21 Nov 2018 - Stockland (ASX:SGP) has exchanged contracts to divest Stockland Bathurst... read more

20 Oct

Aristocrat completes Plarium acquisition

20 Oct 2017 - Aristocrat (ASX:ALL) announces the completion of its Plarium acquisition after... read more

28 Sep

Collection House (ASX:CLH) targeting sustainable growth

28 Sep 2018 - Collection House Limited (ASX:CLH) Chairman, Leigh Berkley discusses new developments... read more

13 Dec

Air New Zealand passengers rise across globe

13 Dec 2017 - Air New Zealand (ASX:AIZ) has seen a rise of 6... read more

10 Jul

Aitken Investments Management’s Charlie Aitken speaks at the SMSF2017 Summit & Investment Expo, Sydney

10 Jul 2017 - Aitken Investments Management CEO Charlie Aitken speaks to FNN at... read more

07 Aug

Paragon Care stronger FY17 profit, EBITA & revenue

07 Aug 2017 - Paragon Care (ASX:PGC) has reported its gross profit rose 26... read more

17 Jan

The a2 Milk Company expands in the US, grows to 5,000 stores

17 Jan 2018 - Dairy and infant formula company The a2 Milk Company (ASX:A2M)... read more

31 Jan

Independence Group’s Nova and Tropicana production delivers for the quarter

31 Jan 2018 - Mining and exploration company Independence Group (ASX:IGO) reports its Nova... read more

15 Feb

Domain Holdings NPAT slips 14.2 per cent

15 Feb 2019 - Domain Holdings Australia (ASX:DHG) today released its results for the... read more

27 Oct

AMP’s Q3 FY17 results in line with expectations

27 Oct 2017 - AMP (ASX:AMP) reports Q3 FY2017 results in line with market... read more